Oxford BioMedica plc 36.2% potential upside indicated by RBC Capital Markets

Oxford BioMedica plc with ticker (LON:OXB) now has a potential upside of 36.2% according to RBC Capital Markets.



RBC Capital Markets set a target price of 1,340 GBX for the company, which when compared to the Oxford BioMedica plc share price of 855 GBX at opening today (01/02/2022) indicates a potential upside of 36.2%. Trading has ranged between 802 (52 week low) and 1,678 (52 week high) with an average of 195,646 shares exchanging hands daily. The market capitalisation at the time of writing is £735,073,091.

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company’s product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.